$LRMR
Larimar Therapeutics, Inc.

2017 Q2 Form 10-Q Financial Statement

#000119312517164257 Filed on May 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.010M $3.590M $5.360M
YoY Change -38.57% -33.02% 76.9%
% of Gross Profit
Research & Development $10.53M $9.677M $12.50M
YoY Change 3.59% -22.57% 22.34%
% of Gross Profit
Depreciation & Amortization $50.00K $41.00K $50.00K
YoY Change 0.0% -18.0% 900.0%
% of Gross Profit
Operating Expenses $13.54M $13.27M $17.86M
YoY Change -10.13% -25.72% 34.87%
Operating Profit -$13.54M -$13.27M -$17.86M
YoY Change -10.13% -25.72% 34.87%
Interest Expense $53.00K $73.00K $160.0K
YoY Change -62.14% -54.38% -24.88%
% of Operating Profit
Other Income/Expense, Net $189.0K $254.0K $121.0K
YoY Change 455.88% 109.92% -152.16%
Pretax Income -$13.35M -$13.01M -$17.74M
YoY Change -11.18% -26.66% 31.7%
Income Tax
% Of Pretax Income
Net Earnings -$13.35M -$13.01M -$17.74M
YoY Change -11.19% -26.64% 31.65%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$5.855M -$5.706M -$7.815M
COMMON SHARES
Basic Shares Outstanding 27.37M shares 27.35M shares 27.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $106.0M $120.7M $166.2M
YoY Change -29.56% -27.4% -29.04%
Cash & Equivalents $31.73M $32.35M $31.45M
Short-Term Investments $74.27M $88.30M $134.7M
Other Short-Term Assets $1.600M $1.400M $1.300M
YoY Change 23.08% 7.69% -23.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $108.0M $118.7M $168.8M
YoY Change -29.5% -29.71% -28.55%
LONG-TERM ASSETS
Property, Plant & Equipment $588.0K $630.0K $954.0K
YoY Change -53.18% -33.96% 844.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $58.00K $59.00K $90.00K
YoY Change -33.33% -34.44% 1.12%
Total Long-Term Assets $880.0K $689.0K $1.188M
YoY Change -47.43% -42.0% 200.76%
TOTAL ASSETS
Total Short-Term Assets $108.0M $118.7M $168.8M
Total Long-Term Assets $880.0K $689.0K $1.188M
Total Assets $108.8M $119.4M $170.0M
YoY Change -29.7% -29.79% -28.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.447M $1.910M $3.146M
YoY Change 72.3% -39.29% -7.58%
Accrued Expenses $2.709M $3.850M $6.739M
YoY Change -45.56% -42.87% 67.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $400.0K $0.00
YoY Change
Long-Term Debt Due $2.100M $2.400M $3.000M
YoY Change -32.26% -20.0% 42.86%
Total Short-Term Liabilities $9.219M $8.597M $12.88M
YoY Change -13.14% -33.26% 35.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.700M
YoY Change -100.0% -100.0% -50.91%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $2.700M
YoY Change -100.0% -100.0% -50.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.219M $8.597M $12.88M
Total Long-Term Liabilities $0.00 $0.00 $2.700M
Total Liabilities $9.219M $8.597M $15.60M
YoY Change -26.76% -44.91% 3.67%
SHAREHOLDERS EQUITY
Retained Earnings -$263.9M -$250.6M -$197.4M
YoY Change 24.23% 26.93% 66.09%
Common Stock $363.6M $361.4M $351.8M
YoY Change 2.51% 2.72% 3.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.63M $110.8M $154.4M
YoY Change
Total Liabilities & Shareholders Equity $108.8M $119.4M $170.0M
YoY Change -29.7% -29.79% -28.17%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$13.35M -$13.01M -$17.74M
YoY Change -11.19% -26.64% 31.65%
Depreciation, Depletion And Amortization $50.00K $41.00K $50.00K
YoY Change 0.0% -18.0% 900.0%
Cash From Operating Activities -$10.18M -$11.68M -$17.76M
YoY Change -29.89% -34.23% 60.14%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $10.00K $400.0K
YoY Change -96.15% -97.5% 1381.48%
Acquisitions
YoY Change
Other Investing Activities $13.99M $8.700M $14.67M
YoY Change 242.89% -40.7% -121.05%
Cash From Investing Activities $13.99M $8.690M $14.27M
YoY Change 266.23% -39.1% -120.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -710.0K -730.0K -660.0K
YoY Change -1.39% 10.61% -100.51%
NET CHANGE
Cash From Operating Activities -10.18M -11.68M -17.76M
Cash From Investing Activities 13.99M 8.690M 14.27M
Cash From Financing Activities -710.0K -730.0K -660.0K
Net Change In Cash 3.100M -3.720M -4.150M
YoY Change -127.15% -10.36% -108.5%
FREE CASH FLOW
Cash From Operating Activities -$10.18M -$11.68M -$17.76M
Capital Expenditures -$10.00K $10.00K $400.0K
Free Cash Flow -$10.17M -$11.69M -$18.16M
YoY Change -28.68% -35.63% 63.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27372851 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31450000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
757000
CY2017Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
23407000
CY2017Q1 us-gaap Notes Payable
NotesPayable
2411000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
111711000
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
116900000
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27350723 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27350723 shares
CY2017Q1 us-gaap Assets
Assets
119371000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
118682000
CY2017Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
63000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000 shares
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
361370000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28632000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
27000
CY2017Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88367000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1910000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
412000
CY2017Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
88304000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-63000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3850000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
379000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Liabilities
Liabilities
8597000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119371000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8597000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
110000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
191000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
82000
CY2017Q1 us-gaap Notes Payable Current
NotesPayableCurrent
2837000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
106000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
630000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
110774000
CY2017Q1 us-gaap Restructuring Reserve
RestructuringReserve
80000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250560000
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1378000
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 zfgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2491000
CY2017Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-22
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001374690
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
80000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
359329000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32352000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2016Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
96922000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2572000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
347000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
96842000
CY2017Q1 zfgn Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
80000
CY2017Q1 zfgn Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
368000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35595000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2008000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
26588000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
123430000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27332551 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27332551 shares
CY2016Q4 us-gaap Assets
Assets
131621000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
130899000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-80000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3733000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Liabilities
Liabilities
9894000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131621000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9894000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
110000
CY2016Q4 us-gaap Notes Payable
NotesPayable
3183000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
61000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3589000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
661000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
121727000
CY2016Q4 us-gaap Restructuring Reserve
RestructuringReserve
376000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237549000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1358000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 zfgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
892000
CY2016Q4 zfgn Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
376000
CY2016Q4 zfgn Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
347000
CY2016Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.31 pure
CY2016 us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
1223000
CY2016 us-gaap Payments For Restructuring
PaymentsForRestructuring
847000
zfgn Net Proceeds From Sale Of Securities
NetProceedsFromSaleOfSecurities
333300000
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
Zafgen, Inc.
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4064974 shares
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3720000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2001000
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3588000
CY2017Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.02 pure
CY2017Q1 us-gaap Depreciation
Depreciation
41000
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12994000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13265000
CY2017Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
7000
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
13265000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-13011000
CY2017Q1 us-gaap Interest Expense
InterestExpense
73000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8691000
CY2017Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
17000
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
32792000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-662000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
100000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
21000
CY2017Q1 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Interest Paid
InterestPaid
59000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
254000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
41493000
CY2017Q1 us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
24000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
132000
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
17000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
40000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-732000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
227000
CY2017Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
320000
CY2017Q1 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
210000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2001000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27350673 shares
CY2017Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
772000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3838927 shares
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4145000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2756000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5360000
CY2016Q1 us-gaap Depreciation
Depreciation
50000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17528000
CY2016Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
72000
CY2016Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
66000
CY2016Q1 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
64000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11679000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
CY2017Q1 dei Trading Symbol
TradingSymbol
ZFGN
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9677000
CY2016Q1 us-gaap Interest Paid
InterestPaid
119000
CY2016Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
121000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
49135000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
695000
CY2016Q1 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
124000
CY2016Q1 zfgn Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
144000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
208000
CY2016Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
55000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
17857000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-17736000
CY2016Q1 us-gaap Interest Expense
InterestExpense
160000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
14273000
CY2016Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
208000
CY2016Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
34462000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4051000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-437000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-17857000
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
13000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-657000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
209000
CY2016Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
409000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17761000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
400000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12497000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2756000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27263435 shares
CY2016Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
712000

Files In Submission

Name View Source Status
0001193125-17-164257-index-headers.html Edgar Link pending
0001193125-17-164257-index.html Edgar Link pending
0001193125-17-164257.txt Edgar Link pending
0001193125-17-164257-xbrl.zip Edgar Link pending
d188131d10q.htm Edgar Link pending
d188131dex311.htm Edgar Link pending
d188131dex312.htm Edgar Link pending
d188131dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zfgn-20170331.xml Edgar Link completed
zfgn-20170331.xsd Edgar Link pending
zfgn-20170331_cal.xml Edgar Link unprocessable
zfgn-20170331_def.xml Edgar Link unprocessable
zfgn-20170331_lab.xml Edgar Link unprocessable
zfgn-20170331_pre.xml Edgar Link unprocessable